Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

J une Jo Lee grew up at the intersection of Korea, California, and Texas. At an early age, she tried to understand why her ...

Obesity costs U.S. health care nearly $173 billion yearly. With more than 200 related complications such as heart disease, ...

This article offers a comprehensive comparison between Hyperliquid and its top competitors—dYdX, Aevo, and GMX.

CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...

Adolescents and young adults are increasingly using GLP-1 receptor agonists for weight management, raising concerns among ...

Read more from Frieden on how Kennedy’s tactics are straight from the anti-vaccine playbook.

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.